NCT07105111

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Neurocrine Biosciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Conditions

• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder
• Major Depressive Disorder
• Tardive Dyskinesia

Interventions

Type	Name	Description
DRUG	Valbenazine	Valbenazine capsules for oral administration.

Timeline

• Start date: 2025-08-29
• Primary completion: 2027-01-01
• Completion: 2027-01-01
• First posted: 2025-08-05
• Last updated: 2026-04-16

Locations

19 sites across 1 country: United States

Regulatory

• FDA-regulated drug study